Therapeutic observance and schizophrenia: Importance of validation of the French translation of Medication Adherence rating scale (MARS) [2];Observance thérapeutique et schizophrénie: Intérêt de la validation de la traduction française du Medication Adherence Rating Scale (MARS)

Encephale

Volumn 30, Issue 4, 2004, Pages 409-410

  Misdrahi, D ^a   Verdoux, H ^a   Llorca, P M ^a   Bayle F J ^a  

^a CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH BEHAVIOR; LETTER; LITERATURE; MEDICATION ADHERENCE RATING SCALE; PATIENT COMPLIANCE; RATING SCALE; SCHIZOPHRENIA; VALIDATION PROCESS;

ANTIPSYCHOTIC AGENTS; FRANCE; HUMANS; LANGUAGE; PATIENT COMPLIANCE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; TRANSLATIONS;

EID: 5644265091     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. BAYLĖ FJ, MISDRAHI D. Observance - Facteurs d'observance - Comment l'améliorer? In JMPM, ed. Du bon usage des psychotropes. Paris (in press: APNET-Association pėdagogique nationale pour l'enseignement de la thérapeutique): Vigot, 2004.
2. DOLDER CR, LACRO JP, LECKLANDS S et al. Interventions to improve antipsychotic medications adherence: review of recent literature. J Clin psychopharmacol 2003; 23 (4): 389-99.
3. DROULOUT T, LIRAUD F, VERDOUX H. Relationships between insight and medication adherence in subjects with psychosis. Encephale 2003; 29 (5): 430-7.
4. FLEISCHHACKER WW, OEHL MA, HUMMER M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 (Suppl 16): 10-3.
5. HAYWOOD TW, KRAVITZ HM, GROSSMAN LS et al. Predicting the « revolving door » phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152 (6): 856-61.
6. HOGAN TP, AWAD AG, EASTWOOD R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13 (1): 177-83.
7. LITTRELL RA, MAINOUS AGd, KAREM FJ et al. Clinical sequelae of overt non-compliance with psychotropic agents. Psychopharmacol Bull 1994; 30 (2): 239-44.
8. MISDRAHI D, LLORCA PM, LANCON C et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002; 28 (3): 266-72.
9. MORISKY DE, GREEN LW, LEVINE DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74.
10. OLFSON M, MECHANIC D, HANSELL S et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51 (2): 216-22.
11. THOMPSON K, KULKARNI J, SERGEJEW AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42 (3): 241-7.
12. VERDOUX H, LENGRONNE J, LIRAUD F et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000; 102 (3): 203-10.
13. WEIDEN P, GLAZER W. Assessment and treatment selection for « revolving door » inpatients with schizophrenia. Psychiatr Q 1997; 68 (4): 377-92.
14. WEIDEN P, OLFSON M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29.
15. ZYGMUNT A, OLFSON M, BOYER CA et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159 (10): 1653-64.